121 related articles for article (PubMed ID: 9065989)
1. Screening for the FV:Q506 mutation--evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis.
Tripodi A; Negri B; Bertina RM; Mannucci PM
Thromb Haemost; 1997 Mar; 77(3):436-9. PubMed ID: 9065989
[TBL] [Abstract][Full Text] [Related]
2. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
Favaloro EJ; Mirochnik O; McDonald D
Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
[TBL] [Abstract][Full Text] [Related]
3. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis.
Dahlbäck B
Thromb Haemost; 1997 Jul; 78(1):483-8. PubMed ID: 9198201
[TBL] [Abstract][Full Text] [Related]
4. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
5. Proposal for objective evaluation of the performance of various functional APC-resistance tests in genotyped patients.
Freyburger G; Javorschi S; Labrouche S; Bernard P
Thromb Haemost; 1997 Nov; 78(5):1360-5. PubMed ID: 9408020
[TBL] [Abstract][Full Text] [Related]
6. [Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population].
Pereira J; Quiroga T; Goycoolea M; Muñoz B; Hidalgo P; Kaltwasser G; Mezzano D
Rev Med Chil; 1996 Jun; 124(6):663-8. PubMed ID: 9041721
[TBL] [Abstract][Full Text] [Related]
7. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
9. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
Wilmer M; Stocker C; Bühler B; Conell B; Calatzis A
Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls.
Svensson PJ; Zöller B; Dahlbäck B
Thromb Haemost; 1997 Feb; 77(2):332-5. PubMed ID: 9157592
[TBL] [Abstract][Full Text] [Related]
11. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. The APC Resistance Study Group.
Rosén S; Johansson K; Lindberg K; Dahlbäck B
Thromb Haemost; 1994 Aug; 72(2):255-60. PubMed ID: 7831662
[TBL] [Abstract][Full Text] [Related]
12. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
Dahlbäck B
Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
Guasch JF; Lensen RP; Bertina RM
Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
[TBL] [Abstract][Full Text] [Related]
14. Standardization of the APC resistance test. Effects of normalization of results by means of pooled normal plasma.
Tripodi A; Chantarangkul V; Negri B; Mannucci PM
Thromb Haemost; 1998 Mar; 79(3):564-6. PubMed ID: 9531041
[TBL] [Abstract][Full Text] [Related]
15. [National evaluation of the diagnosis of activated protein C resistance].
Montiel-Manzano G; de la Peña-Díaz A; Majluf-Cruz A; Cesarman-Maus G; Corona-de la Peña N; Cruz-Cruz D; Gaminio E; Martínez-Murillo C; Mayagoitia T; Miranda-Peralta E; Poblete T; Quintana-Martínez S; Ramírez R; Razo D; Ruiz de Chávez-Ochoa A; Reyes-Núñez VA; Salazar R; Vicencio-Santiago GV; Villa R
Rev Invest Clin; 2003; 55(3):358-69. PubMed ID: 14515684
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the FV:Q506 mutation in unselected oncology patients.
Otterson GA; Monahan BP; Harold N; Steinberg SM; Frame JN; Kaye FJ
Am J Med; 1996 Oct; 101(4):406-12. PubMed ID: 8873512
[TBL] [Abstract][Full Text] [Related]
17. Activated protein C resistance assay performance: improvement by sample dilution with factor V-deficient plasma.
Strobl FJ; Hoffman S; Huber S; Williams EC; Voelkerding KV
Arch Pathol Lab Med; 1998 May; 122(5):430-3. PubMed ID: 9593344
[TBL] [Abstract][Full Text] [Related]
18. Laboratory diagnosis of resistance to activated protein C (APC-resistance).
Bertina RM
Thromb Haemost; 1997 Jul; 78(1):478-82. PubMed ID: 9198200
[No Abstract] [Full Text] [Related]
19. Comparison of an activated partial thromboplastin time with a Russell viper venom time test in screening for factor V(Leiden) (FVR506Q).
Sweeney JD; Blair AJ; King TC
Am J Clin Pathol; 1997 Jul; 108(1):74-7. PubMed ID: 9208981
[TBL] [Abstract][Full Text] [Related]
20. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
Montes MA; Fox EA; Longtine JA; Dorfman DM
Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
